FindTrial
Sign In

A Comparative Study among Intravenous Lignocaine, 2% Lignocaine Nebulisation and 4% Lignocaine Nebulisation in blunting of Laryngeal Response during Intubation, randomised clinical trial

Effect of Lignocaine airway nebulisation vs intravenous lignocaine on intubation response in General anaesthesia patients. A Comparative Randomised clinical trial.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/09/036202
Enrollment
75
Registered
2021-09-03
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: R688- Other general symptoms and signs

Interventions

Intervention1: Lignocaine intravenous: Group 1: Will receive 5 ml of 2% lignocaine nebulisation 10 min prior to induction and equivalent volume of normal saline IV 90 sec before intubation. Group 2:

Sponsors

Pondicherry Institute of Medical Sciences
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1)Patients aged between 18 and 60 yrs. 2)American Society of Anaesthesiologists ASA 1 and ASA 2 patients coming for GA. 3)Patients coming for elective procedures.

Exclusion criteria

Exclusion criteria: 1) Surgery involving the oral, nasopharyngeal, laryngotracheal airway or thyroid. 2) Patients history of respiratory disease (COPD, asthma). 3) History of recent respiratory tract infection. 4) Patients with anticipated difficult intubation and Those requiring > 3 attempts at laryngoscopy and intubation. 5) History of any known allergy to Lignocaine. 6) Patients coming for emergency procedures.

Design outcomes

Primary

MeasureTime frame
Primary objective: To compare hemodynamic responses to Intubation in topical 2% lignocaine and 4% lignocaine patients and compare it with intravenous lignocaine in patients undergoing General anaesthesia. Timepoint: Baseline, 1min, 2min, 3min, 4min, 5min, 10min.—

Secondary

MeasureTime frame
To study any adverse drug reactionsTimepoint: 1min, 2min, 3min, 4min, 5min, 10min—

Countries

India

Contacts

Public ContactRamyavel T

Pondicherry Institute of Medical Sciences

ramyavel1988@gmail.com9487630425

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026